Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bionorica Research GmbH
• Treatments: Dronabinol

Criteria

Inclusion Criteria:

• Diagnosis of multiple sclerosis acc. to McDonald diagnostic criteria

• EDSS score between 3 and 8 (incl.)

• Patients who are in a stable phase of multiple sclerosis

• Patients with MS-related central neuropathic pain for at least 3 months

Exclusion Criteria:

• Severe concomitant diseases

• Certain concomitant therapies (in particular: pain influencing concomitant therapies)

• Dronabinol intake within the last 12 months prior to study entry or Marihuana use within one month prior to study entry